Loteprednol Etabonate/Brimonidine tartrate

氯替泼诺/酒石酸溴莫尼定

Report date: 2026/03/09 20:02:04

Base Information

Drug NameLoteprednol Etabonate/Brimonidine tartrate

Drug Alias NameOCU-310

ClassificationSmall molecules > Steroids

Mechanisms of ActionAdrenergic receptors alpha-2 agonistsGlucocorticoid receptor agonistsCytosolic phospholipase A2 agonists

TargetsAdrenergic receptors alpha-2Glucocorticoid receptorCytosolic phospholipase A2

Therapy Area/IndicationsXerophthalmia

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

Global Highest StatusPending (Phase 3 Clinical)

Highest Status in ChinaN/A

Originator CompaniesOcugen Inc

China Registration ClassN/A

Active CompaniesN/A

Inactive CompaniesOcugen Inc

Active IndicationsN/A

Inactive IndicationsXerophthalmia

ATC CodeN/A